Combined use of the high heparin step and optical density to optimize diagnostic sensitivity and specificity of an anti-PF4/heparin enzyme-immunoassay

被引:30
作者
Althaus, Karina [1 ]
Strobel, Ulrike [1 ]
Warkentin, Theodore E. [2 ]
Greinacher, Andreas [1 ]
机构
[1] Ernst Moritz Arndt Univ Greifswald, Inst Immunol & Transfus Med, D-17489 Greifswald, Germany
[2] McMaster Univ, Dept Pathol & Mol Med, Hamilton, ON, Canada
关键词
Heparin-induced thrombocytopenia; HIT; laboratory testing; heparin; PF4; INDUCED THROMBOCYTOPENIA; CONFIRMATORY PROCEDURE; CARDIOPULMONARY BYPASS; UNFRACTIONATED HEPARIN; CLINICAL-SIGNIFICANCE; INDUCED ANTIBODIES; RISK-FACTORS; VALUES; IGG; PLATELET-FACTOR-4;
D O I
10.1016/j.thromres.2011.05.003
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: IgG-specific anti-PF4/heparin enzyme-immunoassays (EIAs) are sensitive but not specific for platelet-activating antibodies, the cause of heparin-induced thrombocytopenia (HIT). Two features of EIA reactivity predict for presence of HIT antibodies - the magnitude of a positive result (in optical density [OD] units) and the inhibition of reactivity at high heparin concentrations - but their combined utility remains uncertain. Objective: To determine for an IgG-specific EIA how the OD values of a positive reaction and its inhibition by high heparin can be optimally combined. Methods: We screened 1,000 consecutive patients with suspected HIT using an IgG-specific PF4/heparin in-house EIA with and without high heparin (100 IU/mL); and by the heparin-induced platelet activation test. Results: Platelet-activating antibodies were rarely detected (<0.2%) when the IgG-specific EIA was negative at the conventional cut-off (OD, 0.5). However, an OD cut-off of 1.0 resulted in an unacceptable loss of sensitivity (14/83 = 17%) for detecting platelet-activating antibodies. The high heparin step increased specificity for platelet-activating antibodies from 72% to 89% without loss of sensitivity when applied to weak-positive sera (OD <= 1.0). However, decreased sensitivity was observed with strong-positive sera (OD > 1.0): 11/69 such sera (16%) that did not show >40% inhibition by high heparin nevertheless contained platelet-activating antibodies. Conclusion: Specificity of an IgG-specific EIA for detecting platelet-activating antibodies can be optimized by applying the high heparin inhibition step to weak-positive reactions (0.5- <= 1.0 OD). However, applying the high heparin inhibition step to strong-positive reactions (>1.0 OD) in our in-house assay risks falsely classifying a serum as negative for platelet-activating antibodies. (C) 2011 Elsevier Ltd. All rights reserved.
引用
收藏
页码:256 / 260
页数:5
相关论文
共 33 条
  • [1] AMIRAL J, 1992, THROMB HAEMOSTASIS, V68, P95
  • [2] [Anonymous], HEPARIN INDUCED THRO
  • [3] Prospective evaluation of PF4/heparin immunoassays for the diagnosis of heparin-induced thrombocytopenia
    Bakchoul, T.
    Giptner, A.
    Najaoui, A.
    Bein, G.
    Santoso, S.
    Sachs, U. J. H.
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 (08) : 1260 - 1265
  • [4] Performance characteristics of two commercially available IgG-specific immunoassays in the assessment of heparin-induced thrombocytopenia (HIT)
    Bakchoul, Tamam
    Giptner, Astrid
    Bein, Gregor
    Santoso, Sentot
    Sachs, Ulrich J. H.
    [J]. THROMBOSIS RESEARCH, 2011, 127 (04) : 345 - 348
  • [5] Thrombocytopenia in medical-surgical critically ill patients: prevalence, incidence, and risk factors
    Crowther, MA
    Cook, DJ
    Meade, MO
    Griffith, LE
    Guyatt, GH
    Arnold, DM
    Rabbat, CG
    Geerts, WH
    Warkentin, TE
    [J]. JOURNAL OF CRITICAL CARE, 2005, 20 (04) : 348 - 353
  • [6] The new ID-heparin/PF4: antibody test for rapid detection of heparin-induced antibodies in comparison with functional and antigenic assays
    Eichler, P
    Raschke, R
    Lubenow, N
    Meyer, O
    Schwind, P
    Greinacher, A
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2002, 116 (04) : 887 - 891
  • [7] Heparin-induced thrombocytopenia: a prospective study on the incidence, platelet-activating capacity and clinical significance of antiplatelet factor 4/heparin antibodies of the IgG, IgM, and IgA classes
    Greinacher, A.
    Juhl, D.
    Strobel, U.
    Wessel, A.
    Lubenow, N.
    Selleng, K.
    Eichler, P.
    Warkentin, T. E.
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2007, 5 (08) : 1666 - 1673
  • [8] Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosis
    Greinacher, A
    Farner, B
    Kroll, H
    Kohlmann, T
    Warkentin, TE
    Eichler, P
    [J]. THROMBOSIS AND HAEMOSTASIS, 2005, 94 (01) : 132 - 135
  • [9] Heparin-induced thrombocytopenia: towards standardization of platelet factor 4/heparin antigen tests
    Greinacher, A.
    Ittermann, T.
    Bagemuehl, J.
    Althaus, K.
    Fuerll, B.
    Selleng, S.
    Lubenow, N.
    Schellong, S.
    Sheppard, J. I.
    Warkentin, T. E.
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2010, 8 (09) : 2025 - 2031
  • [10] GREINACHER A, 1992, THROMB HAEMOSTASIS, V67, P545